The medical insurance drug list is about to be adjusted, and 344 drugs have passed the preliminary formal examination

On September 6, the National Medical Insurance Bureau issued an announcement

Announcement on the Announcement of Drugs and Related Information That Have Passed preliminary formal examination for the adjustment of the National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalogue in 2022

What is preliminary formality examination?

What is preliminary formality examination?

The preliminary formal review is a preliminary review

According to the "Interim Measures for the Administration of Drugs in Basic Medical Insurance", the national medical insurance drug catalogue is adjusted to implement the enterprise declaration system

Does passing the preliminary formal examination mean that it has been included in the national medical insurance drug list?

Does passing the preliminary formal examination mean that it has been included in the national medical insurance drug list?

According to the "Interim Measures for the Administration of Drugs in Basic Medical Insurance" and the "2022 National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalogue Adjustment Work Plan", the adjustment of the medical insurance drug catalogue is divided into enterprise declaration, formal review, expert review, negotiation and bidding, etc.

Only by successfully passing all aspects of the catalogue adjustment can it finally be included in the national medical insurance drug catalogue

What are the changes in the enterprise declaration and preliminary form review of the adjustment of the national medical insurance drug list in 2022 compared with last year?

From 9:00 on July 1, 2022 to 17:00 on July 14, 2022, the national medical insurance information platform received a

After review, 344 drugs passed the preliminary form examination, and the proportion of passing was 70%.

How do you think that some of the drugs that are currently more expensive on the market have passed the preliminary form examination?

How do you think that some of the drugs that are currently more expensive on the market have passed the preliminary form examination?

Since its inception, the National Medical Insurance Bureau has resolutely implemented the decision-making and deployment of the Party Central Committee and the State Council, always firmly grasped the functional positioning of basic medical insurance "guaranteeing the basics", insisted on doing its best, doing what it could, and realistically determining the scope of protection; Always adhere to the sound and sustainable, take the affordability of the medical insurance fund and the insured people as the basis for the adjustment of the catalogue, and significantly reduce the price of exclusive drugs through access negotiations and other means; Always focus on the balance between the basic medical needs of the masses and the progress of clinical technology, improve accessibility and maintain fairness

This year, some of the more expensive drugs passed the preliminary form examination, indicating only that the drug met the conditions for declaration and was qualified to

Whether such drugs can eventually enter the national medical insurance drug list also needs to be strictly evaluated in many ways, including economy, and the exclusive drugs that pass the review must be negotiated, and the non-exclusive drugs must be bid, and only after negotiation or bidding can they be included in the list

What are the key considerations for the treatment of covid-19 in the National Medical Insurance Drug Catalogue?

In order to do a good job in the prevention and control of the new crown epidemic, the National Medical Insurance Bureau adheres to the principle of "people-centered" and focuses on the overall situation of epidemic prevention and control, and in the early stage of the epidemic, it issued the "two guarantees" policy of "ensuring that patients do not affect medical treatment due to cost problems and ensuring that hospitals are not affected by payment policies", temporarily including relevant drugs in the scope of medical insurance payment, providing strong support

In the context of the normalization of epidemic prevention and control, since the first implementation of the self-declaration system for medical insurance drug catalogue enterprises in 2020, the National Medical Insurance Bureau has attached great importance to the treatment of new crown pneumonia drugs, and has taken "drugs included in the diagnosis and treatment plan for new coronavirus pneumonia" as one

Since the first implementation of the self-declaration system for medical insurance drug catalogue enterprises in 2020, the National Medical Insurance Bureau has attached great importance to the treatment of new crown pneumonia drugs, and has taken "drugs included in the diagnosis and treatment plan for new coronavirus pneumonia" as one

How will the work be carried out after this announcement?

How will the work be carried out after this announcement?

In the next step, according to the feedback received during the publicity period, the relevant information will be further verified, and the scope of drugs that will eventually pass the formal examination will be determined, and announced to the public